NorthStar Medical Radioisotopes and Convergent Therapeutics have entered into a supply agreement for the actinium-225 (Ac-225) medical radioisotope.
Under the deal, NorthStar's Ac-225, a radioactive alpha-particle emitter, will be used in Convergent's proprietary drug candidate, CONV 01-α. The drug is a monoclonal antibody conjugated with actinium-225.
The drug candidate is a major component of Convergent's peptide receptor radionuclide therapy (PRRT) technology. PRRT targets prostate-specific membrane antigen present in prostate cancer cells.